The addition of a spatially defined overlay of transcriptomics to cytotoxicity/histological findings, or biomarker expression/localization image data, adds mechanistic underpinning to these findings.
SpheroMatrices microTMA technology is a platform for analyzing both phenotype and transcriptomics in human-relevant 3D microtissue/MPS models. Following in life exposure to drugs/chemicals, microtissues are fixed and arrayed in a single plane in a microscope slide-sized geometric grid replicating the plate layout of the original experiment. We then make physical serial sections through all spheroids in the TMA simultaneously, approximately 10 sections per experiment. This allows for slide-based analyses of histology, target/off target biomarker expression (using immunohistochemistry and/or RNAscope), and transcriptomics across all tissues simultaneously, permitting direct comparison between treatment groups as well as between slides.
TempO-Seq profiling complements SpheroMatrices microTMA technology in that it works especially well with fixed tissue and requires much less RNA to provide a readout than microarrays or RNA-Seq, while providing equivalent results (Bushel et al 2018).
MicroMatrices uses Zeiss Laser Capture Microscopy to dissect microtissue sections from SpheroMatrices microTMA slides, or sub regions within microtissues, for TempO-Seq transcriptomics. Likewise, we can use the same approach to dissect regions of interest, mapped via immunohistochemistry, within tissue samples.
Please get in touch to discuss how transcriptome profiling using SpheroMatrices, Laser capture and TempO-Seq can add spatially defined mechanistic understanding to phenotypic observations in microtissue/MPS experiments, or other types of tissue samples.
on an interactive, step by step basis. Collaborations can begin with pilot projects which can then be scaled up to larger research programs, according to your requirements.